Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
123.82
+1.56 (1.28%)
At close: Feb 23, 2026, 4:00 PM EST
124.05
+0.23 (0.19%)
After-hours: Feb 23, 2026, 7:59 PM EST
Merck & Co. Employees
Merck & Co. had 75,000 employees as of December 31, 2024. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
$866,813
Profits / Employee
$243,387
Market Cap
307.32B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
| Dec 31, 2018 | 69,000 | 0 | - |
| Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2016 | 68,000 | 0 | - |
| Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
| Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
| Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
| Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
| Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
| Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
| Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 92,900 |
| Pfizer | 81,000 |
| Novartis AG | 75,267 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 68,629 |
| AbbVie | 57,000 |
MRK News
- 9 hours ago - US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost - Reuters
- 15 hours ago - Merck creates separate oncology arm ahead of Keytruda patent loss - Invezz
- 17 hours ago - Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff. - Barrons
- 18 hours ago - Merck Evolves Human Health Operating Structure to Support Portfolio Execution - Business Wire
- 18 hours ago - Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports - Reuters
- 19 hours ago - Merck is establishing a separate cancer unit. The reorganization of its pharmaceutical business is aimed at bolstering product launches ahead of a key patent loss. - WSJ
- 19 hours ago - Harbor Large Cap Value Fund Q4 2025 Portfolio Review - Seeking Alpha
- 1 day ago - Merck: Why Investors Should Remain Bullish Despite Patent Risks - Seeking Alpha